caspofungin acetate
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Aspergillosis
Conditions
Aspergillosis, Candidiasis
Trial Timeline
Apr 1, 2004 → Jul 1, 2007
NCT ID
NCT00082524About caspofungin acetate
caspofungin acetate is a phase 2 stage product being developed by Merck for Aspergillosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00082524. Target conditions include Aspergillosis, Candidiasis.
What happened to similar drugs?
8 of 16 similar drugs in Aspergillosis were approved
Approved (8) Terminated (6) Active (6)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00635648 | Phase 3 | Completed |
| NCT00330395 | Phase 2 | Completed |
| NCT00250432 | Phase 3 | Completed |
| NCT00379964 | Phase 3 | Completed |
| NCT00292071 | Phase 2 | Completed |
| NCT00082524 | Phase 2 | Completed |
Competing Products
20 competing products in Aspergillosis